Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68788-4026

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-4026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Phamaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

Figure6 (Image 10)

This is a description of different dosages of a medication called Duloretine (120 mg, 60 mg, and 20 mg once daily) compared to a placebo group. The chart shows the percentage of patients improved in pain from baseline across different time points.*

FDA Label Image

Figure 7 (Image 11)

This is a comparison chart displaying the percentage of patients improved with Duloxetine Delayed-Release 60mg once daily compared to Placebo. The data shows the percentage of patients improved ranging from 10% to 100% and indicates a percent improvement in pain from baseline.*

FDA Label Image

Figure8 (Image 12)

This text provides data on the percentage of patients improved in a study comparing a placebo to Duloxetine Delayed-Release at doses of 60 mg and 120 mg once daily. The chart shows the percent improvement in pain from baseline using the BOCF (Baseline Observation Carried Forward) method. It appears to present results at various time points during the study.*

FDA Label Image

Figure9 (Image 13)

This is a chart showing the percentage of patients improved in pain from baseline with a placebo and Duloxetine Delayed-Release 60 mg once daily. The chart displays the percent improvement in pain at various intervals. The values shown are 210, 230, 250, 260, 70, 80, 90, and 100. The data is for evaluating the effectiveness of the medication in managing pain.*

FDA Label Image

Figure10 (Image 14)

This information relates to the percentage of patients improved after receiving either a placebo or Duloxetine Delayed-Release in doses of 60/120 mg once daily. The data includes numerical values representing the percentage improvement in pain from baseline through a BOCF analysis.*

FDA Label Image

1 (Image 16)

FDA Label Image

1 (Image 17)

FDA Label Image

Duloxetine Delayed-release Cap Usp 30mg (Image 19)

This text contains information about a medication called Duloxetine Delayed-Release Cap, which is a generic for Cymbalta. Each capsule contains 33.7mg of Duloxetine Hydrochloride, equivalent to 30mg of Duloxetine. It provides details about the manufacturer, storage conditions, warnings, and the expiration date. It emphasizes that the drug should not be transferred to anyone other than the patient for whom it was prescribed due to federal law.*

FDA Label Image

1 (Image 2)

FDA Label Image

Duloxetine Delayed-release Cap Usp 60mg (Image 20)

This text provides detailed information about Duloxetine Delayed-Release Capsules, a generic form of Cymbalta that contains 60mg of duloxetine hydrochloride. The description includes the composition of the capsules, storage instructions, manufacturer details, and a warning. It highlights the importance of not transferring the drug to anyone other than the prescribed patient.*

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

FDA Label Image

Figure1 (Image 5)

This text provides information on the Proportion of Patients with Relapse based on Treatment with Placebo and Duloxetine Delayed-Release Capsules over time. The data includes a graph showing the Time from Randomization to Relapse in days, calculated using the Kaplan-Meier estimator method.*

FDA Label Image

Figure2 (Image 6)

This data shows the proportion of patients experiencing a relapse over time after receiving either a placebo or Duloxetine Delayed-Release Capsules. The Kaplan-Meier estimator method was used to analyze the time from randomization to relapse in days.*

FDA Label Image

Figure3 (Image 7)

This text shows different dosages of duloxetine and placebo with the percentage of patients improved and the percent improvement in pain from baseline. The dosages mentioned are 80mg, 60mg, and 20mg of Duloxetine, as well as a placebo. The data seems to be related to a study or analysis evaluating the effectiveness of these different dosages in pain management or treatment.*

FDA Label Image

Figure4 (Image 8)

This text contains data on the percentage of patients improved along with the percent improvement in pain from baseline for various treatments, including Duloxetine at different dosages and Placebo. This data can be used to evaluate the effectiveness of the treatments in pain management.*

FDA Label Image

Figure5 (Image 9)

This text provides information on the percentage of patients improved with different treatments, such as Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo. It also includes a scale for percent improvement in pain from baseline.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.